



Dr Palayakotai Raghavan



专业背景

2008年至今；纽约州查帕夸 (Chappaqua)

Nanorx Inc, 创始人兼首席执行官

研发了一种经过专利保护，由食物制成的新型纳米脂质聚己糖，具有许多治疗特性，并在品牌名称 Metadichol[®] 下销售。

1996 年至 2008 年；纽约州查帕夸 (Chappaqua) MCR Pharma 创始人

研发了一种基于纳米技术的催化剂，可以一步骤将任何类型的油转化为生物柴油。这项属商业机密的催化剂已获得准证供全球各地的公司使用。

1990年至1994年：Boehringer Ingleheim

Pharmaceuticals 首席科学家，药物化学

进行了新产品包括抗生素、艾滋病药物和Cox-2抑制剂的

市场情报调查和标杆研究。在艾滋病和炎症研究领域成功合成了药物实体，并开发了可转移到试验工厂的升级式生产方法。

制定了第1阶段至第3阶段临床研究的协议。

1987年至1990年：Ciba-Geigy Corporation,

纽约州阿德斯利 (Ardsley) 临床前药物代谢高级科学家

制定了心血管、炎症和中枢神经系统领域化合物的第1

阶段至第3阶段临床研究的协议。建立了一个分子建模设施，用于药物代谢研究应用。开发了一种模型方法，用于预测药物与黑色素的结合以及一种用于预测药物通过皮肤扩散的方法。还合成了用于药物代谢研究的放射性标记化合物，并开发并监督了员工。

研究背景

1978年至1980年：德国穆尔海姆的马克斯·普朗克研究所学会 (Max-Planck Society) 研究员。研究天然产物合成的光化学方法。

1980年至1981年：加拿大谢布鲁克 (Sherbrooke) 大学高级研究合伙人

开发了光化学合成路线，用于合成半萜、单萜、二萜等生物上有用的天然产物。

1982年至1983年：印度 Ranbaxy

Laboratories 高级研究科学家

开发了一种新的工业路线，用于生产重要的商业性麻醉药物哌替啶 (Pentazocine)。该过程将药物成本从每

千克1100美元降低到250美元。

1985年至1987年：纽约哥伦比亚大学

研究合伙人

工作涉及设计合成酶，用于治疗白内障和其他相关眼部疾病。设计并合成了具有肽附属物的有机硒化合物，模拟了酶谷胱甘肽过氧化物酶 (Glutathione Peroxidase)。这些分子是使用分子建模技术设计的。通过研究酶的活性位点的拓扑和结构，设计了一个目标分子，以近似模拟活性位点的形状和活性，然后进行了合成和活性测试。

教育背景

1979年：美国俄勒冈州科尔瓦利斯，俄勒冈州立大学 (Oregon State University)

博士学位 - 有机化学，论文题目：开发大环抗生素 Methymycin的方法。

1972：年印度孟买印度理工学院 (Indian Institute of Technology Bombay)

硕士学位 - 化学

语言能力

精通德语

基本法语

精通淡米尔语，坎纳达语和印地语 (印度语言)

出版刊物和专利名称：

- Raghavan, P.R. US Patents: Policosanol nanoparticles 8,722,093 (2014); 9,034,383 (2015); 9,006,292 (2015). In addition 40 other International patents approved in EU, China, Japan, Canada, Australia, Korea, Singapore, Mexico, India, Russia, South Africa, Chile.
- Raghavan, P.R. Metadichol[®] a Sirtuin Modulator for Anti-Aging Therapies P.R. Raghavan This is a preprint; it has not been peer-reviewed by a journal. <https://doi.org/10.21203/rs.3.rs-3199226/v2>
- Raghavan P.R. Metadichol, An agonist that expresses the anti-aging gene Klotho in various cell lines." DOI : [10.21203/rs.3.rs-2635049/v1](https://doi.org/10.21203/rs.3.rs-2635049/v1)
- Raghavan P.R. Metadichol[®] induced expression of neuronal transcription factors with Human Dermal cells. <https://doi.org/10.21203/rs.3.rs-1983481/v1>
- P.R. Raghavan. Metadichol is a natural ligand for expressing Yamanaka reprogramming factors in somatic and primary cancer cell lines This is a preprint; it has not been peer-reviewed by a journal. <https://doi.org/10.21203/rs.3.rs-1727437/v4>
- P R Raghavan , Metadichol[®] is a nano lipid emulsion that expresses all 48 nuclear receptors in stem and somatic cells T. <https://doi.org/10.21203/rs.3.rs-1797646/v4>.
- P R. Raghavan. Metadichol Treatment of Fibroblasts and Embryonic Stem Cells Regulates Key Cardiac Progenitors. Cardiology and Cardiovascular Medicine. 7 (2023): 322-330.
- P R. Raghavan, "Metadichol[®]: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro", BioMed Research International, vol. 2022, Article ID 1558860, 14 pages, 2022. <https://doi.org/10.1155/2022/1558860>
- Raghavan P.R., Yogisha S., Anand S., Purushotham G.V. (2019) Metadichol[®] a Sialidase Inhibitor. J Stem Cell Res Ther 9: 449. doi:10.4172/2157-7633.1000449
- Raghavan PR (2019) Metadichol[®] A Novel Inverse Agonist of Thyroid Receptor and its Applications in Thyroid Diseases. Biol Med (Aligarh) 11: 458. doi: 10.4172/0974-8369.1000458/
- Raghavan PR (2019) The Quest for Immortality: Introducing Metadichol[®] a Novel Telomerase Activator. Stem Cell Res Ther 9: 446. doi: 10.4172/2157-7633.1000446
- Raghavan PR (2018) A Multi Gene Targeting Approach to Treating Liver Diseases with Metadichol[®]. J Cytokine Biol 3: 126. doi: 10.4172/2576-3881.100012.
- Raghavan PR (2019) Metadichol[®] and CD33 Expression in Umbilical Cord Cells. Stem Cell Res Ther 9: 443. doi: 10.4172/2157-7633.1000443.
- Raghavan PR (2018) Metadichol[®] a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines. J Cancer Sci Ther 10: 351-357.
- Raghavan. P.R. Umbilical Cord Cells Treatment with Metadichol[®] IRS Proteins and GLUT4 Expression and Implications for Diabetes. J Stem Cell Res Ther 2018, 8:6 DOI: 10.4172/2157-7633.1000429
- Raghavan PR (2018) Metadichol[®] and CD34 Expression in Umbilical Cord Cells. J Stem Cell Res Ther 8: 409. doi: 10.4172/2157-7633.1000409
- Raghavan, P.R. Metadichol[®] and Healthy Skin: One Approach many Possible Cures J Clin Exp Dermatol Res 2018, 9:1. DOI: 10.4172/2155-9554.1000445
- Raghavan PR (2018) Metadichol[®], Vitamin C and GULO Gene Expression in Mouse Adipocytes. Biol Med (Aligarh) 10: 426. doi: 10.4172/0974-8369.1000426.
- Raghavan PR (2017) Metadichol, A Novel ROR Gamma Inverse Agonist and Its Applications in Psoriasis. J Clin Exp Dermatol Res 8: 433. doi: 10.4172/2155-9554.1000433
- Raghavan PR (2017); Metadichol[®]. A Novel Inverse Agonist of Aryl Hydrocarbon Receptor (AHR) and NRF2 Inhibitor. J Cancer Sci Ther 9: 661-668. doi: 10.4172/1948-5956.1000489
- Raghavan PR (2017). Metadichol[®] Induced High Levels of Vitamin C: Case Studies. Vitam Miner 6: 169. doi: 10.4172/2376-1318.1000169

- Raghavan PR (2017) Metadichol[®] and Red Cell Distribution Width (RDW) in CKD patients. J Stem Cell Res Ther 7: 392.
- Raghavan P.R. (2017) Metadichol[®] and Vitamin C Increase In Vivo, an Open-Label Study. Vitam. Miner 6: 163
- Raghavan, P.R. (2017). Rheumatoid Arthritis and Osteoporosis: A Case Study. J Arthritis 6:240. Doi 10.4172/2167-7921.1000240.
- Raghavan, P.R. Systolic and Diastolic BP Control in Metabolic Syndrome Patients with Metadichol[®] a Novel Nano Emulsion Lipid. J Cardiol & Cardiovasc Ther 2017; 5(2): 555660. DOI: 10.19080/JOCCT.2017.05.555660.
- Raghavan, P.R. 2017; Metadichol[®] A Novel Nano Lipid; GPR 120 Agonist. Int J Diabetes Complications. vol1, Issue1, 1-4
- Raghavan, P.R. 2017; Metadichol[®] and MRSA Infections: A Case Report, J Infect Dis Ther 2017, 5:2, 100317. DOI: 10.4172/2332-0877.1000317
- Raghavan, P.R. , 2017; Improving Longevity with Metadichol[®] by inhibiting Bcat-1 Gene. Journal of Aging Science. 5:1, DOI: 10.4172/2329-8847.1000174
- Raghavan, P.R., 2016; In vitro Inhibition of Zika Virus by Metadichol[®]. A Novel Nano Emulsion Lipid, J Immunol Tech Infect Dis 5:4; doi: 10.4172/2329-9541.100015
- Raghavan, P.R., 2016; Inhibition of Dengue and other enveloped viruses by Metadichol[®], a novel Nano emulsion Lipid, Journal of the of Healing Outcomes, Vol 8, No 31, 19-25
- Raghavan P.R., 2016; Metadichol and Type 2 Diabetes A case report. Journal of the Science of Healing Outcomes: 2016; Vol 8, No 32, 5-10.
- Raghavan, P.R. 2010; Case Report of Type 1. Diabetes, Journal of the Science of Healing Outcomes, 2010, Vol 2, No 8-9, page 24.
- Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1), John Proudfoot, P.R. Raghavan et al., J. Med. Chem., 4830-4838 (1995)
- A Novel, Dipyrindodiazepinone Inhibitor of HIV-1 Reverse Transcriptase acts through a non-substrate Binding site, Joe C. Wu, T.C. Warren, J. Adams, J. Proudfoot, J. Skiles, P.R. Raghavan, Clark Perry, Ian Potocki, Peter R. Ferina and Peter M. Grob, Biochemistry. 30, 2022 (1991)
- Prediction of drug-melanin binding using molecular modeling, P. R. Raghavan, P. A. Zane, S. L. Tripp, Experientia, 46, 78 (1990)
- Physicochemical modeling of tissue distribution using whole body autoradiography and molecular modeling techniques, P. A. Zane, Shirley Brindle, Arlene O'Buck, P. R. Raghavan, S. L. Tripp, Pharmaceutical Research, 7, 935 (1990)
- A. Spector, S. R. Wilson, P. Zucker, R-R. C. Huang and P.R. Raghavan Synthesis of Glutathione peroxidase analogs, Lens Eye Toxic Res 1989;6(4):773-80.
- P. R. Raghavan, S. R. Wilson and A. Spector The development of synthetic compounds with Glutathione peroxidase activity, Association for Research in Vision and Ophthalmology, Sarasota, Florida, May 1987, Abstract No. 45, 391
- The reaction of Cyclopropyl ketones with acetyl methanesulfonate, an efficient ring opening under neutral conditions with regioselective enol acetate formation and stereo controlled nucleophilic addition, P.R. Raghavan and M. Demuth, Helv. Chim. Acta., 62, 2338 (1979)
- Photochemical high yield preparation of Tricyclo (3, 3, 0, 02, 8) Octan-3-one. Potential synthons for polycyclopentanoid terpenes and Prostacycline analogs, M. Demuth, P. R. Raghavan, C. Carter, K. 41. Nakano and Kurt Schaffner, Helv. Chim. Acta., 63, 2440 (1980)
- Regio and stereoselective functionalization of Tricyclo (3, 3, 0, 02, 8) Octan-3-one, A Potential synthon for polycyclopentanoid terpenes and prostacycline analogs, M. Demuth, S. Chandrashekar, K. Nakano, P. R. Raghavan and Kurt Schaffner, Helv. Chim. Acta., 63, 2446 (1980)